When the FDA approves a drug, it approves it for a specific indication — a defined patient population with a defined disease or condition. But once a drug is on the market, physicians are legally permitted to prescribe it for any use they believe is in their patient’s best interest, including uses not mentioned on the FDA-approved label. This is called off-label prescribing, and it is far more prevalent than most retail investors realize. Understanding off-label drug use is important for biotech investors because it affects how drug revenue is generated, how commercial opportunity is assessed, and what supplemental label expansion is worth to a company.
The Short Answer
| Off-label drug use refers to prescribing or using an FDA-approved drug in a manner not included in its approved labeling — for a different indication, a different patient population (such as children when approved only for adults), a different dose, or a different route of administration. The FDA regulates drug approval and manufacturer promotion, but does not regulate the practice of medicine. Physicians have the legal authority to prescribe approved drugs off-label based on their clinical judgment. |
Why Off-Label Prescribing Exists and How Common It Is
The practice of off-label prescribing arose from the fundamental distinction the US regulatory system draws between drug approval — a manufacturer-driven regulatory process — and medical practice — a physician-driven clinical judgment. The FDA approves drugs for specific uses based on the data submitted by manufacturers. But clinical science advances constantly, and physicians often have compelling scientific rationale or clinical experience supporting a drug’s use in a population or condition that the manufacturer never formally studied.
In oncology, off-label prescribing is especially prevalent. Estimates suggest that between 20% and 60% of cancer drug prescriptions in certain settings are written off-label. This reflects the reality that cancer drug development often focuses on a specific cancer type initially, but the drug’s mechanism of action may be relevant across multiple tumor types. Oncologists frequently prescribe based on tumor biology rather than waiting for formal approval in every applicable cancer subtype.
For pediatric medicine, off-label use has historically been even more common — the majority of drugs approved for adults were never formally studied in children, yet children require treatment. This gap led to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act, which provide incentives for manufacturers to study drugs in pediatric populations and ultimately add pediatric labeling.
What Manufacturers Can and Cannot Do Regarding Off-Label Use
FDA regulations strictly limit what drug manufacturers can say or do to promote off-label use. A manufacturer cannot advertise, market, or proactively promote its approved drug for any use not included in the FDA-approved label. Doing so constitutes illegal off-label promotion, which has resulted in multi-billion dollar settlements and criminal charges against major pharmaceutical companies.
However, manufacturers can respond to unsolicited requests from physicians for information about off-label uses, and they can distribute peer-reviewed scientific publications discussing off-label research. The line between permissible scientific exchange and illegal promotion is actively monitored by the FDA and the Department of Justice.
Why Off-Label Revenue Matters for Biotech Investors
Off-label prescribing can constitute a significant portion of an approved drug’s total revenue — sometimes the majority of it. For investors, this creates an important analytical nuance: a drug’s commercial success is not always bounded by its approved indication. A drug approved in one cancer type may generate substantial off-label revenue across other tumor types if the biological rationale is compelling and physicians adopt it widely.
At the same time, off-label revenue is structurally less stable than labeled revenue. Insurance coverage for off-label use varies by plan, clinical setting, and the strength of the supporting evidence. A drug used primarily off-label is vulnerable to reimbursement restrictions, payer policies, and the accumulation of negative data in the off-label indication. Investors should treat off-label revenue as real but consider it less defensible than on-label revenue supported by formal FDA approval.
Label Expansion — Converting Off-Label to On-Label
When off-label use is substantial and growing, companies have a commercial incentive to formally study the new indication and file a supplemental NDA (sNDA) to add it to the label. A formal label expansion creates an on-label indication that manufacturers can legally promote, that payers are more reliably obligated to cover, and that creates a more defensible commercial position.
Label expansion programs — Phase 2 or Phase 3 trials in new indications for already-approved drugs — are among the most clearly commercially motivated clinical trials in the industry. Investors tracking approved-drug companies should pay attention to label expansion programs as potential catalysts: each new indication that converts from off-label to on-label expands the addressable market and the company’s ability to promote and protect that revenue.
What This Does Not Guarantee
| Widespread off-label use of a drug does not guarantee that a formal clinical trial in the off-label indication will succeed. Anecdotal clinical experience and small retrospective studies support many off-label practices that have subsequently failed in prospective randomized trials. Investors should not treat high off-label adoption as surrogate clinical evidence. A label expansion program must be evaluated on the same clinical trial standards as any other development program. |
Key Takeaways
- Off-label drug use means prescribing an FDA-approved drug outside its approved indication, patient population, dose, or route of administration — which physicians are legally permitted to do
- In oncology, between 20% and 60% of prescriptions in some settings are written off-label, reflecting the biology-driven approach physicians use in cancer treatment
- Manufacturers cannot legally promote off-label use, but physicians can prescribe off-label based on clinical judgment
- Off-label revenue can constitute a significant portion of a drug’s total sales but is less defensible than on-label revenue due to variable payer coverage
- Label expansion programs — filing supplemental NDAs for new indications — convert off-label use to formally approved and promotable use
- The Best Pharmaceuticals for Children Act and Pediatric Research Equity Act were created to address the widespread off-label use of adult drugs in pediatric patients
- High off-label adoption does not validate that a formal clinical trial will succeed in the same indication — prospective trial evidence is a different standard
Sources
1. FDA — Off-Label Use: https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
2. FDA — Supplemental NDAs: https://www.fda.gov/drugs/types-applications/supplemental-applications-prescription-drugs
3. NIH — Off-Label Drug Use in Oncology: https://pubmed.ncbi.nlm.nih.gov
4. Best Pharmaceuticals for Children Act: https://www.fda.gov/science-research/pediatric-products/best-pharmaceuticals-children-act-bpca
Disclaimer
This article is based on publicly available regulatory information, company filings, and authoritative industry sources. All information was current as of the date of publication. BioTech Stocks Daily has not received compensation from any company referenced in this article in connection with this coverage.
This article contains references to forward-looking statements and clinical projections. Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those projected. Past clinical results do not guarantee future outcomes.
The information provided in this article is for informational and educational purposes only and does not constitute financial, investment, or medical advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decision.
For full terms, see our Disclaimer.
